Putnam Global Health Care Fund C (PCHSX)
30.67
+0.21
(+0.69%)
USD |
Jun 06 2025
Key Stats
Customize
Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
---|---|---|---|
1.80% | 1.464B | 1.46% | 36.00% |
1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
-170.47M | -10.04% | Upgrade | Upgrade |
Basic Info
Investment Strategy | |
The Fund seeks capital appreciation. Under normal circumstances, the Fund invests at least 80% of its assets in securities of companies in the health care industries. |
General | |
Security Type | Mutual Fund |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Global Peer Group | Equity Sector Healthcare |
Peer Group | Global Health/Biotechnology Funds |
Global Macro | Equity Industry Sector |
US Macro | World Sector Equity Funds |
YCharts Categorization | -- |
YCharts Benchmark | -- |
Prospectus Objective | Global Health/Biotechnology Funds |
Fund Owner Firm Name | Franklin Templeton |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
74
-519.15M
Peer Group Low
21.14M
Peer Group High
1 Year
% Rank:
78
-170.47M
-5.960B
Peer Group Low
49.90M
Peer Group High
3 Months
% Rank:
74
-1.603B
Peer Group Low
17.71M
Peer Group High
3 Years
% Rank:
68
-12.79B
Peer Group Low
170.17M
Peer Group High
6 Months
% Rank:
76
-3.844B
Peer Group Low
24.57M
Peer Group High
5 Years
% Rank:
68
-20.44B
Peer Group Low
656.86M
Peer Group High
YTD
% Rank:
76
-2.922B
Peer Group Low
93.35M
Peer Group High
10 Years
% Rank:
58
-38.18B
Peer Group Low
615.44M
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of June 08, 2025.
Asset Allocation
As of April 30, 2025.
Type | % Net |
---|---|
Cash | 2.74% |
Stock | 96.84% |
Bond | 0.13% |
Convertible | 0.00% |
Preferred | 0.00% |
Other | 0.29% |
Top 10 Holdings
Name | % Weight | Price | % Change |
---|---|---|---|
Eli Lilly and Co | 12.88% | 769.88 | 0.55% |
UnitedHealth Group Inc | 7.41% | 303.22 | 2.49% |
AbbVie Inc | 6.22% | 189.83 | 1.26% |
AstraZeneca PLC | 5.01% | 144.32 | 1.10% |
Boston Scientific Corp | 4.81% | 102.09 | -0.72% |
Intuitive Surgical Inc | 4.37% | 557.08 | -0.18% |
Innoviva Inc | 4.02% | 21.58 | 1.94% |
McKesson Corp | 3.67% | 712.89 | 0.18% |
Johnson & Johnson | 3.61% | 155.03 | 0.89% |
Novartis AG | 3.57% | 117.60 | 1.97% |
Fees & Availability
Fees | |
Actual 12B-1 Fee | 1.00% |
Actual Management Fee | 0.61% |
Administration Fee | -- |
Maximum Front Load | -- |
Maximum Deferred Load | 1.00% |
Maximum Redemption Fee | 0.00% |
General Availability | |
Available for Insurance Product | -- |
Available for RRSP | -- |
Purchase Details | |
Open to New Investors |
|
Minimum Initial Investment | 500.00 None |
Minimum Subsequent Investment | 0.00 None |
Basic Info
Investment Strategy | |
The Fund seeks capital appreciation. Under normal circumstances, the Fund invests at least 80% of its assets in securities of companies in the health care industries. |
General | |
Security Type | Mutual Fund |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Global Peer Group | Equity Sector Healthcare |
Peer Group | Global Health/Biotechnology Funds |
Global Macro | Equity Industry Sector |
US Macro | World Sector Equity Funds |
YCharts Categorization | -- |
YCharts Benchmark | -- |
Prospectus Objective | Global Health/Biotechnology Funds |
Fund Owner Firm Name | Franklin Templeton |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Fundamentals
General | |
Distribution Yield | -- |
Dividend Yield TTM (6-6-25) | 0.00% |
30-Day SEC Yield | -- |
7-Day SEC Yield | -- |
Stock | |
Weighted Average PE Ratio | 37.13 |
Weighted Average Price to Sales Ratio | 8.113 |
Weighted Average Price to Book Ratio | 9.738 |
Weighted Median ROE | 45.38% |
Weighted Median ROA | 5.43% |
ROI (TTM) | 8.95% |
Return on Investment (TTM) | 8.95% |
Earning Yield | 0.0358 |
LT Debt / Shareholders Equity | 2.938 |
As of April 30, 2025
Growth Metrics
EPS Growth (1Y) | 20.59% |
EPS Growth (3Y) | 9.60% |
EPS Growth (5Y) | 9.37% |
Sales Growth (1Y) | 15.49% |
Sales Growth (3Y) | 13.82% |
Sales Growth (5Y) | 15.54% |
Sales per Share Growth (1Y) | 15.78% |
Sales per Share Growth (3Y) | 11.61% |
Operating Cash Flow - Growth Ratge (3Y) | 3.34% |
As of April 30, 2025
Fund Details
Top Portfolio Holders
Name | % Weight |
---|---|
Portfolio A | 5.00% |
Portfolio B | 3.50% |
Portfolio C | 2.25% |
Excel Add-In Codes
Name: =YCI("M:PCHSX", "name") |
Broad Asset Class: =YCI("M:PCHSX", "broad_asset_class") |
Broad Category: =YCI("M:PCHSX", "broad_category_group") |
Prospectus Objective: =YCI("M:PCHSX", "prospectus_objective") |
To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |